Objectives: Up to 50% of heart failure (HF) patients may be frail and have worse clinical outcomes than non-frail patients. The benefits of HF-specific pharmacotherapy (beta-blockers, ACE-inhibitors/angiotensin-receptor-blockers and mineralocorticoid-receptor-antagonist) in this population are unclear. This study explored whether HF-specific pharmacotherapy improves outcomes in frail hospitalised HF patients.
Design: Observational, multicentre, cross-sectional study.
Settings: Tertiary care hospitals.
Participants: One thousand four hundred and six hospitalised frail HF patients admitted between 1 January 2013 and 31 December 2020.
Measures: The Hospital Frailty Risk Score (HFRS) determined frailty status and patients with HFRS ≥5 were classified as frail. The primary outcomes included the days alive and out of hospital (DAOH) at 90 days following discharge, 30-day and 180-day mortality, length of hospital stay (LOS) and 30-day readmissions. Propensity score matching (PSM) compared clinical outcomes depending on the receipt of HF-specific pharmacotherapy.
Results: Of 5734 HF patients admitted over a period of 8 years, 1406 (24.5%) were identified as frail according to the HFRS and were included in this study. Of 1406 frail HF patients, 1025 (72.9%) received HF-specific pharmacotherapy compared with 381 (27.1%) who did not receive any of these medications. Frail HF patients who did not receive HF-specific pharmacotherapy were significantly older, with higher creatinine and brain natriuretic peptide but with lower haemoglobin and albumin levels (p<0.05) when compared with those frail patients who received HF medications. After PSM frail patients on treatment were more likely to have an increased DAOH (coefficient 16.18, 95% CI 6.32 to 26.04, p=0.001) than those who were not on treatment. Both 30-day (OR 0.30, 95% CI 0.23 to 0.39, p<0.001) and 180-day mortality (OR 0.43, 95% CI 0.33 to 0.54, p<0.001) were significantly lower in frail patients on HF treatment but, there were no significant differences in LOS and 30-day readmissions (p>0.05).
Conclusion: This study found an association between the use of HF-specific pharmacotherapy and improved clinical outcomes in frail HF hospitalised patients when compared to those who were not on treatment.
Trial Registration Number: ANZCTRN383195.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486223 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2021-059905 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changing the paradigm in heart failure: shifting from treatment to prevention.
Heart Fail Rev
January 2025
Department of Cardiology, Kaiser Permanente San Francisco Medical Center, 2425 Geary Boulevard, San Francisco, CA, 94115, USA.
Article Synopsis
- Heart failure (HF) is a growing global health issue, linked to aging populations and various health conditions, shifting the focus from treatment to prevention.
- The American Heart Association introduced the PREVENT models for estimating the long-term risk of cardiovascular diseases and HF, although they still have limitations in various demographics and risk factors.
- New medications like SGLT2 inhibitors and GLP1 receptor agonists show promise in preventing HF, necessitating a refined approach in risk assessment to effectively allocate these costly treatments to those most in need.
Challenges to heart failure medication prescribing post-hospitalization.
Int J Pharm Pract
September 2024
Department of Pharmacy, Cabrini Hospital, Malvern, Melbourne, VIC 3144, Australia.
Objectives: To determine the prevalence of heart failure (HF) medication prescribing on discharge post-HF-related admission.
Methods: A retrospective audit was conducted for 216 HF admissions over a period of 6 months; medication data from electronic records were collected for analysis.
Key Findings: The prevalence of HF medication prescribing on discharge was: 32.
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
Eur J Heart Fail
July 2024
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Aims: Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores.
Methods And Results: We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively.
Nanotechnology-based techniques for hair follicle regeneration.
Biomaterials
November 2023
Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal. Electronic address:
Article Synopsis
- - The hair follicle (HF) contains multipotent stem cells and traditional hair repair methods like drugs and transplants have limitations, leading to exploration of advanced nanotechnology for HF regeneration.
- - Recent research has identified wound-induced hair neogenesis (WIHN) as a promising mechanism for hair follicle regeneration, expanding the understanding beyond embryonic development.
- - The review discusses various nanotechnology strategies for targeted hair regeneration, covering areas such as hair cycle modulation, progenitor cell stimulation, and the potential regulatory challenges in developing these technologies.
Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation.
Curr Probl Cardiol
January 2024
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA. Electronic address:
Optimal medical therapy (OMT) in patients with coronary artery disease (CAD) and/or heart failure (HF) is underused despite the established benefits of these medications. Cardiac rehabilitation (CR) may be one place where OMT could be promoted. We sought to describe the prevalence and characteristics of OMT use in patients with CAD or HF undergoing CR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!